EMA begins review of Morpho Sys CD19 monoastytasitamab to treat lymphoma
-
Last Update: 2020-05-29
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
The European Medicines Agency (EMA) has begun a review of MorphoSys targeting CD19's monophonoid tafasitamab (MOR208), which, if approved, could pose a challenge to Novartis and Gilead's CAR-T therapyU.Sregulators accepted a marketing application from MorphoSus and its partner Incyte's tafasitamab to treat adult patients with recurrent or incurable diffuse large B-cell lymphoma (DLBCL) who are not suitable for stem cell transplantationPhase 2 L-MIND results showed that the overall remission rate was 60 percent, including 43 percent, in patients who combined tafasitamab with Celgene's RevlimidNovartis' Kymriah and Gilead's Yescarta (axicabagene cilolecel) CAR-T therapy, high doses of chemotherapy were needed, and many patients, especially the elderly, were not physically strong enough to tolerate the treatmentDLBCL is the most common non-Hodgkin's lymphoma (NHL) among adults worldwide, accounting for 40 percent of all cases, and is a very aggressive disease -- about 30-40% of patients do not respond to initial treatment or relapse, which means an urgent need for new treatments
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
